Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co ( (HK:1349) ) has issued an announcement.
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co recently entered into an agreement with the Bank of China to subscribe to a structured deposit product worth RMB200 million. This transaction, using temporary idle proceeds from the public issuance of A shares, is considered a disclosable transaction under the Listing Rules but is exempt from shareholder approval. The deposit product is principal-guaranteed with a floating return, linked to the central parity price of Gold/USD, and assessed as low-risk by the Bank of China.
More about Shanghai Fudan Zhangjiang Bio Pharmaceutical Co
For detailed information about 1349 stock, go to TipRanks’ Stock Analysis page.
